Evidence map›Paper›PMID 35939803›Full record

ArticleJournal of medicinal chemistry2022

Rational Design and Optimization of m

Sarah Huff, Indrasena Reddy Kummetha, Lingzhi Zhang, Lingling Wang, William Bray, Jiekai Yin, Vanessa Kelley, Yinsheng Wang, Tariq M Rana

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
5.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 63 citations in OpenAlex.

  1. The Role of NMedComm · 2026
    Review
  2. Review
  3. Emerging roles of RNA mInternational journal of oncology · 2026
    Review
  4. RNA mCell biology and toxicology · 2026
    Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. mJournal for immunotherapy of cancer · 2025
    Review
  10. Review
  11. RNA mCell investigation · 2025
    Article
  12. Review
  13. Regulation and application of mScience China. Life sciences · 2025
    Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Epigenetics-targeted drugs: current paradigms and future challenges.Signal transduction and targeted therapy · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Sarah HuffDivision of Genetics, Department of Pediatrics, Center for Drug Discovery Innovation, Program in Immunology, Institute for Genomic Medicine, University of California San Diego, 9500 Gilman Drive MC 0762, La Jolla, California 92093, United States.
Indrasena Reddy KummethaDivision of Genetics, Department of Pediatrics, Center for Drug Discovery Innovation, Program in Immunology, Institute for Genomic Medicine, University of California San Diego, 9500 Gilman Drive MC 0762, La Jolla, California 92093, United States.
Lingzhi ZhangDivision of Genetics, Department of Pediatrics, Center for Drug Discovery Innovation, Program in Immunology, Institute for Genomic Medicine, University of California San Diego, 9500 Gilman Drive MC 0762, La Jolla, California 92093, United States.
Lingling WangDivision of Genetics, Department of Pediatrics, Center for Drug Discovery Innovation, Program in Immunology, Institute for Genomic Medicine, University of California San Diego, 9500 Gilman Drive MC 0762, La Jolla, California 92093, United States.
William BrayDivision of Genetics, Department of Pediatrics, Center for Drug Discovery Innovation, Program in Immunology, Institute for Genomic Medicine, University of California San Diego, 9500 Gilman Drive MC 0762, La Jolla, California 92093, United States.ORCID 0000-0003-2414-0190
Jiekai YinEnvironmental Toxicology Graduate Program and Department of Chemistry, University of California, Riverside, California 92521, United States.
Vanessa KelleyDivision of Genetics, Department of Pediatrics, Center for Drug Discovery Innovation, Program in Immunology, Institute for Genomic Medicine, University of California San Diego, 9500 Gilman Drive MC 0762, La Jolla, California 92093, United States.
Yinsheng WangEnvironmental Toxicology Graduate Program and Department of Chemistry, University of California, Riverside, California 92521, United States.
Tariq M RanaDivision of Genetics, Department of Pediatrics, Center for Drug Discovery Innovation, Program in Immunology, Institute for Genomic Medicine, University of California San Diego, 9500 Gilman Drive MC 0762, La Jolla, California 92093, United States.ORCID 0000-0001-9558-5766
University of California San Diego · USUniversity of California, Riverside · US

Funding

UCSD Cancer Center Training Program in Drug DevelopmentT32CA121938 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Michael Bouvet, Dwayne G. Stupack · 2006 to 2026
$10.3M
NCI NIH HHS T32 CA121938
6 · The paper itself

Abstract

Aberrant regulation of

Indexed as

Antineoplastic AgentsGlioblastomaStomach NeoplasmsAdenosineAlpha-Ketoglutarate-Dependent Dioxygenase FTOHumansPhosphatidylinositol 3-KinasesRNARNA, MessengerAdenosineAlpha-Ketoglutarate-Dependent Dioxygenase FTOAntineoplastic AgentsFTO protein, humanPhosphatidylinositol 3-KinasesRNARNA, Messenger

Identifiers

PMID35939803
PMCPMC9421652
OpenAlexW4292311314

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.